Clot-busting drug for stroke blockages up to 24 hours
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a medicine given through a vein to break up blood clots in medium-sized brain arteries. It may help people who had a stroke between 4.5 and 24 hours ago and cannot have the standard clot-removal procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke caused by a blockage in a medium-sized brain artery.
- It has been between 4.5 and 24 hours since you were last known to be well.
- You have some disability from the stroke, such as weakness, vision problems, or trouble speaking.
- You are not planning to have a procedure to remove the clot directly from the artery.
- You have not had major bleeding, recent surgery, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called recombinant human prourokinase for people having an ischemic stroke (a stroke from a blocked blood vessel). The drug is given through an IV within 4.5 hours of symptoms to help restore blood flow and potentially reduce disability.
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
This trial tests giving a clot-dissolving medicine (rhPro-UK) through a vein before a procedure to remove a large blood clot in the brain. It is for people who had a stroke 4.5 to 24 hours ago and are already scheduled for clot removal. The goal is to see if the medicine helps improve blood flow and outcomes.
This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.